Skip to main content

Table 2 Characteristics of the randomized placebo-controlled trials considered for the guideline in chronic migraine

From: Correction to: European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention

Study

Study phase

Treatment regimen

Duration of treatment

Participants (n)

Women (%)

Age range

(years)

Definition of chronic migraine

Preventive treatment

(% using)

Exclusion by preventive failure

(n. of drugs/ categories)

Erenumab

 Tepper, 2017 [45]

II

70 mg monthly sc

140 mg monthly sc

3 months

667

79–87

18–65

ICHD-3, beta version

Not allowed

> 3

Fremanezumab

 Bigal, 2015 [26]

II

225 mg monthly sc (675 mg ld)

3 months

264

85–86

18–65

ICHD-3, beta version

38–43

> 3

 HALO CM [41]

III

225 mg monthly sc (675 mg ld)

675 mg quarterly sc

3 months

1130

87–88

18–70

ICHD-3, beta version

20–22

≥2

Galcanezumab

 REGAIN [31]

III

120 mg monthly sc (240 mg ld)

240 mg monthly sc

3 months

1117

82–87

18–65

ICHD-3, beta version (required at least 1 headache-free day per month)

13–16

> 2

  1. sc: subcutaneous; ld loading dose